中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 3
Mar.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(3): 725-728

Role of microRNA-125b in the development and progression of various chronic liver diseases

DOI: 10.3969/j.issn.1001-5256.2021.03.046
  • 1.

    Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, Nanning 530021, China

  • 2.

    Department of Physiology, School of Basic Medical Sciences

  • Received Date: 2020-09-05
  • Accepted Date: 2020-10-30
  • Published Date: 2021-03-20
    Abstract
  • MicroRNA (miRNA) is a type of small non-coding RNA and acts as a post-transcriptional regulator of gene expression. This article briefly describes the etiology of various chronic liver diseases, including metabolic dysfunction-associated fatty liver disease, chronic hepatitis B, chronic hepatitis C, chronic drug-induced liver injury, liver cirrhosis, and hepatocellular carcinoma, and summarizes related reports on microRNA-125b which enters different signal transduction pathways and plays the same or contradictory regulatory role in the same liver disease or pathological process by targeting different target genes, so as to provide insights into the research on the pathogenesis of various chronic liver diseases and the establishment of non-invasive differential methods.

     

    • FullText(HTML)
  • loading
    • References(48)
  • [1]
    ZHANG SL, PENG CJ, FENG ZJ, et al. Mechanism of action of microRNA in the regulation of hepatic ischemia－reperfusion injury[J]. J Clin Hepatol, 2019, 35(7): 1629-1631. DOI: 10.3969/j.issn.1001-5256.2019.07.045

    张世龙, 彭慈军, 冯赞杰, 等. microRNA调控肝缺血再灌注损伤的作用机制[J]. 临床肝胆病杂志, 2019, 35(7): 1629-1631. DOI: 10.3969/j.issn.1001-5256.2019.07.045
    [2]
    JABANDZIEV P, BOHOSOVA J, PINKASOVA T, et al. The emerging role of noncoding rnas in pediatric inflammatory bowel disease[J]. Inflamm Bowel Dis, 2020, 26(7): 985-993. DOI: 10.1093/ibd/izaa009
    [3]
    SALIMINEJAD K, KHORRAM KHORSHID HR, SOLEYMANI FARD S, et al. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods[J]. J Cell Physiol, 2019, 234(5): 5451-5465. DOI: 10.1002/jcp.27486
    [4]
    MENS M, GHANBARI M. Cell cycle regulation of stem cells by microRNAs[J]. Stem Cell Rev Rep, 2018, 14(3): 309-322. DOI: 10.1007/s12015-018-9808-y
    [5]
    WANG JK, WANG Z, LI G. MicroRNA-125 in immunity and cancer[J]. Cancer Lett, 2019, 454: 134-145. DOI: 10.1016/j.canlet.2019.04.015
    [6]
    SUN YM, LIN KY, CHEN YQ. Diverse functions of miR-125 family in different cell contexts[J]. J Hematol Oncol, 2013, 6: 6. DOI: 10.1186/1756-8722-6-6
    [7]
    FOUAD Y, WAKED I, BOLLIPO S, et al. What's in a name? Renaming 'NAFLD' to 'MAFLD'[J]. Liver Int, 2020, 40(6): 1254-1261. DOI: 10.1111/liv.14478
    [8]
    ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. e1. DOI: 10.1053/j.gastro.2019.11.312
    [9]
    ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039
    [10]
    ZHANG ZC, LIU Y, XIAO LL, et al. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice[J]. J Hepatol, 2015, 63(6): 1466-1475. DOI: 10.1016/j.jhep.2015.07.037
    [11]
    LI W, SUN Z, CHEN C, et al. Sirtuin7 has an oncogenic potential via promoting the growth of cholangiocarcinoma cells[J]. Biomed Pharmacother, 2018, 100: 257-266. DOI: 10.1016/j.biopha.2018.02.007
    [12]
    SHIN J, HE M, LIU Y, et al. SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease[J]. Cell Rep, 2013, 5(3): 654-665. DOI: 10.1016/j.celrep.2013.10.007
    [13]
    LANINI S, USTIANOWSKI A, PISAPIA R, et al. Viral hepatitis: Etiology, epidemiology, transmission, diagnostics, treatment, and prevention[J]. Infect Dis Clin North Am, 2019, 33(4): 1045-1062. DOI: 10.1016/j.idc.2019.08.004
    [14]
    INOUE T, TANAKA Y. The role of hepatitis B core-related antigen[J]. Genes (Basel), 2019, 10(5): 357. DOI: 10.3390/genes10050357
    [15]
    TAO YC, WANG ML, WANG M, et al. Quantification of circulating miR-125b-5p predicts survival in chronic hepatitis B patients with acute-on-chronic liver failure[J]. Dig Liver Dis, 2019, 51(3): 412-418. DOI: 10.1016/j.dld.2018.08.030
    [16]
    DENG W, ZHANG X, MA Z, et al. MicroRNA-125b-5p mediates post-transcriptional regulation of hepatitis B virus replication via the LIN28B/let-7 axis[J]. RNA Biol, 2017, 14(10): 1389-1398. DOI: 10.1080/15476286.2017.1293770
    [17]
    ZHANG Z, CHEN J, HE Y, et al. miR-125b inhibits hepatitis B virus expression in vitro through targeting of the SCNN1A gene[J]. Arch Virol, 2014, 159(12): 3335-3343. DOI: 10.1007/s00705-014-2208-y
    [18]
    SPEARMAN CW, DUSHEIKO GM, HELLARD M, et al. Hepatitis C[J]. Lancet (London, England), 2019, 394(10207): 1451-1466. DOI: 10.1016/S0140-6736(19)32320-7
    [19]
    ELEMEERY MN, BADR AN, MOHAMED MA, et al. Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients[J]. World J Gastroenterol, 2017, 23(21): 3864-3875. DOI: 10.3748/wjg.v23.i21.3864
    [20]
    SHWETHA S, SHARMA G, RAHEJA H, et al. Interaction of miR-125b-5p with Human antigen R mRNA: Mechanism of controlling HCV replication[J]. Virus Res, 2018, 258: 1-8. DOI: 10.1016/j.virusres.2018.09.006
    [21]
    SHWETHA S, KUMAR A, MULLICK R, et al. HuR displaces polypyrimidine tract binding protein to facilitate La binding to the 3' untranslated region and enhances hepatitis C virus replication[J]. J Virol, 2015, 89(22): 11356-11371. DOI: 10.1128/JVI.01714-15
    [22]
    DAI CY, TSAI YS, CHOU WW, et al. The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection[J]. Oncotarget, 2018, 9(13): 11291-11302. DOI: 10.18632/oncotarget.24129
    [23]
    YE H, NELSON LJ, GÓMEZ DEL MORAL M, et al. Dissecting the molecular pathophysiology of drug-induced liver injury[J]. World J Gastroenterol, 2018, 24(13): 1373-1385. DOI: 10.3748/wjg.v24.i13.1373
    [24]
    CHEN C, LIU YH, CHENG SB, et al. The hepatoprotective effects of XCHD and MgIG against methotrexate-induced liver injury and inflammation in rats through suppressing the activation of AIM2 inflammasomes[J]. Pathol Res Pract, 2020, 216(4): 152875. DOI: 10.1016/j.prp.2020.152875
    [25]
    YE JH, HO YF, ON AW, et al. Trends in reporting drug-associated liver injuries in Taiwan: A focus on amiodarone[J]. Int J Clin Pharm, 2018, 40(4): 911-920. DOI: 10.1007/s11096-018-0698-5
    [26]
    WANG C, HUANG W, LIN J, et al. Triclosan-induced liver and brain injury in zebrafish (Danio rerio) via abnormal expression of miR-125 regulated by PKCα/Nrf2/p53 signaling pathways[J]. Chemosphere, 2020, 241: 125086. DOI: 10.1016/j.chemosphere.2019.125086
    [27]
    LI Y, REN Q, ZHU L, et al. Involvement of methylation of MicroRNA-122, -125b and -106b in regulation of Cyclin G1, CAT-1 and STAT3 target genes in isoniazid-induced liver injury[J]. BMC Pharmacol Toxicol, 2018, 19(1): 11. DOI: 10.1186/s40360-018-0201-x
    [28]
    AYDIN MM, AKÇALI KC. Liver fibrosis[J]. Turk J Gastroenterol, 2018, 29(1): 14-21.
    [29]
    SMITH A, BAUMGARTNER K, BOSITIS C. Cirrhosis: Diagnosis and management[J]. Am Fam Physician, 2019, 100(12): 759-770.
    [30]
    CHEN Z, JAIN A, LIU H, et al. Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis[J]. J Pharmacol Exp Ther, 2019, 370(3): 695-702. DOI: 10.1124/jpet.118.256156
    [31]
    CAI Q, CHEN F, XU F, et al. Epigenetic silencing of microRNA-125b-5p promotes liver fibrosis in nonalcoholic fatty liver disease via integrin α8-mediated activation of RhoA signaling pathway[J]. Metabolism, 2020, 104: 154140. DOI: 10.1016/j.metabol.2020.154140
    [32]
    YOU K, LI SY, GONG J, et al. MicroRNA-125b promotes hepatic stellate cell activation and liver fibrosis by activating RhoA signaling[J]. Mol Ther Nucleic Acids, 2018, 12: 57-66. DOI: 10.1016/j.omtn.2018.04.016
    [33]
    RINGELHAN M, PFISTER D, O'CONNOR T, et al. The immunology of hepatocellular carcinoma[J]. Nat Immunol, 2018, 19(3): 222-232. DOI: 10.1038/s41590-018-0044-z
    [34]
    XU J, AN P, WINKLER CA, et al. Dysregulated microRNAs in hepatitis B virus-related hepatocellular carcinoma: Potential as biomarkers and therapeutic targets[J]. Front Oncol, 2020, 10: 1271. DOI: 10.3389/fonc.2020.01271
    [35]
    WANG JK, WANG Z, LI G. MicroRNA-125 in immunity and cancer[J]. Cancer Lett, 2019, 454: 134-145. DOI: 10.1016/j.canlet.2019.04.015
    [36]
    FRITSCH R, HOEPPNER J. Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 285-291. DOI: 10.1080/17474124.2019.1573143
    [37]
    ABDELGALIL AA, ALKAHTANI HM, AL-JENOOBI FI. Sorafenib[J]. Profiles Drug Subst Excip Relat Methodol, 2019, 44: 239-266.
    [38]
    CHANG QQ, PENG Y, WANG GJ, et al. Clinical research progress of small molecule tyrosine kinase inhibitors as anti-hepatocellular carcinoma agents[J]. Chin J Clin Pharmacol Ther, 2019, 24(8): 948-956.

    常青青, 彭英, 王广基, 等. 抗肝癌小分子酪氨酸激酶抑制剂的临床研究进展[J]. 中国临床药理学与治疗学, 2019, 24(8): 948-956.
    [39]
    REN WW, LI DD, CHEN X, et al. MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy[J]. Cell Death Dis, 2018, 9(5): 547. DOI: 10.1038/s41419-018-0592-z
    [40]
    HU J, ZHANG J, SUN F, et al. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor[J]. Anticancer Drugs, 2019, 30(7): e0746. http://www.ncbi.nlm.nih.gov/pubmed/31305292
    [41]
    LI J, FANG L, YU W, et al. MicroRNA-125b suppresses the migration and invasion of hepatocellular carcinoma cells by targeting transcriptional coactivator with PDZ-binding motif[J]. Oncol Lett, 2015, 9(4): 1971-1975. DOI: 10.3892/ol.2015.2973
    [42]
    ZHOU W, WENG J, WU K, et al. Silencing of TAZ inhibits the motility of hepatocellular carcinoma cells through autophagy induction[J]. Cancer Manag Res, 2019, 11: 8743-8753. DOI: 10.2147/CMAR.S215466
    [43]
    QIANG L, HE YY. Autophagy deficiency stabilizes TWIST1 to promote epithelial-mesenchymal transition[J]. Autophagy, 2014, 10(10): 1864-1865. DOI: 10.4161/auto.32171
    [44]
    HUA S, QUAN Y, ZHAN M, et al. miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1[J]. Cancer Cell Int, 2019, 19: 203. DOI: 10.1186/s12935-019-0919-6
    [45]
    LEE D, XU IM, CHIU DK, et al. Induction of oxidative stress through inhibition of thioredoxin reductase 1 is an effective therapeutic approach for hepatocellular carcinoma[J]. Hepatology, 2019, 69(4): 1768-1786. DOI: 10.1002/hep.30467
    [46]
    SONG S, YANG Y, LIU M, et al. MiR-125b attenuates human hepatocellular carcinoma malignancy through targeting SIRT6[J]. Am J Cancer Res, 2018, 8(6): 993-1007. http://europepmc.org/articles/PMC6048406/?report=classic
    [47]
    KIM JK, NOH JH, JUNG KH, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b[J]. Hepatology, 2013, 57(3): 1055-1067. DOI: 10.1002/hep.26101
    [48]
    ZHANG Y, LI H, CHANG H, et al. MTP18 overexpression contributes to tumor growth and metastasis and associates with poor survival in hepatocellular carcinoma[J]. Cell Death Dis, 2018, 9(10): 956. DOI: 10.1038/s41419-018-0987-x
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (504) PDF downloads(30) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return